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Bisphenol A induces coronary 
endothelial cell necroptosis by 
activating RIP3/CamKII dependent 
pathway
p. Reventun  1, S. Sanchez-esteban1, A. cook1, i. cuadrado2, c. Roza  1,  
R. Moreno-Gomez-toledano1, c. Muñoz1, c. Zaragoza3, R. J. Bosch1 & M. Saura  1*
Epidemiological studies link long term exposure to xenoestrogen Bisphenol-A to adverse cardiovascular 
effects. Our previous results show that BPA induces hypertension by a mechanism involving CamKII 
activation and increased redox stress caused by eNOS uncoupling. Recently, CamKII sustained 
activation has been recognized as a central mediator of programmed cell death in cardiovascular 
diseases, including necroptosis. However, the role of necroptosis in cardiac response to BPA had not yet 
been explored. Mice exposed to BPA for 16 weeks showed altered heart function, electrical conduction, 
and increased blood pressure. Besides, a stress test showed ST-segment depression, indicative of 
cardiac ischemia. The hearts exhibited cardiac hypertrophy and reduced vascularization, interstitial 
edema, and large hemorrhagic foci accompanied by fibrinogen deposits. BPA initiated a cardiac 
inflammatory response, up-regulation of M1 macrophage polarization, and increased oxidative stress, 
coinciding with the increased expression of CamKII and the necroptotic effector RIP3. In addition, cell 
death was especially evident in coronary endothelial cells within hemorrhagic areas, and Evans blue 
extravasation indicated a vascular leak in response to Bisphenol-A. Consistent with the in vivo findings, 
BPA increased the necroptosis/apoptosis ratio, the expression of RIP3, and CamKII activation in 
endothelial cells. Necrostatin-1, an inhibitor of necroptosis, alleviated BPA induced cardiac dysfunction 
and prevented the inflammatory and hemorrhagic response in mice. Mechanistically, silencing of RIP3 
reversed BPA-induced necroptosis and CamKII activation in endothelial cells, while inhibition of CamKII 
activation by KN-93 had no effect on RIP3 expression but decreased necroptotic cell death suggesting 
that BPA induced necroptosis is mediated by a RIP 3/CamKII dependent pathway. Our results reveal 
a novel pathogenic role of BPA on the coronary circulation. BPA induces endothelial cell necroptosis, 
promotes the weakening of coronary vascular wall, which caused internal ventricular hemorrhages, 
delaying the reparative process and ultimately leading to cardiac dysfunction.
Bisphenol A (BPA) is a ubiquitously used chemical with endocrine-disrupting activity. Many of BPA effects are 
dependent on its ability to interact with estrogen receptors1,2. Due to its widespread use, humans are exposed 
continuously to accumulative doses of BPA. Significant exposure often occurs by consuming food and beverages 
contaminated with BPA and in dental procedures, so that up to 92.6% of the human population has detectable 
BPA levels in their bodies3,4. Epidemiological studies have demonstrated that higher BPA urine concentrations 
are associated with increased morbidity and mortality from cardiovascular diseases5,6, and several studies in 
humans and animal models have suggested a causative role for BPA in cardiovascular disease including hyper-
tension, atherosclerosis, cardiac hypertrophy and arrythmias7–10. Recently, it has been reported that a life long 
exposure to BPA in rodents produces arrhythmogenic effects11. Moreover, it has been demonstrated that acute 
or chronic exposure to BPA, impaired functional recovery after myocardial infarction due to a reduced ability to 
induce macrophage polarization from proinflammatory to a reparative state12,13. Indeed, there is an increasing 
concern about BPA higher bioaccumulation in developing organisms and special vulnerable populations such 
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as patients exposed to BPA leaching from medical devices, people handling thermal paper receipts, or plastic 
industry workers4,13,14.
Despite all the evidence, there is not a consensus about the extent of cardiac damage caused by BPA. Moreover, 
the mechanisms by which BPA exposure induces cardiovascular disease remains to be fully elucidated. Many 
reports rely on cardiomyocyte-specific mechanisms to explain the adverse cardiac effects of BPA. So, most studies 
reported alterations on electrical conduction15,16, dysregulation of the contractile apparatus17,18, and metabolic 
abnormalities on cardiomyocytes19, but little attention has been focused on the coronary circulation; indeed, 
BPA can promote the development of atherosclerosis20. A connection between urinary BPA and hypertension 
has been established in human and animal models, and the role of BPA in peripheral disease has been identi-
fied8,21. Recently, it has been reported that although BPA itself does not affect the coronary response in coronary 
ischemia/reperfusion, it reduces coronary flow after reperfusion, and when administered together with estrogens, 
it counteracts their protective effect during reperfusion22.
Our previous studies demonstrated a direct effect of orally administered BPA in mice, causing hyperten-
sion and endothelial dysfunction due to endothelial nitric oxide synthase (eNOS) uncoupling via Angiotensin 
II/Ca2+-CamKII pathway23. In the heart, calmodulin-dependent protein kinase II (CamKII) regulates cardi-
omyocyte Ca2+ handling, contractility, and cell survival; however, sustained CamKII activation is recognized 
to promote heart failure24, arrhythmia25, and sudden cardiac death26. Besides, chronic CamKII activation con-
tributes to endothelial-dependent vascular disease in diabetes and hypertension, which can also impact cardiac 
function. Recently, CamKII sustained activation has been recognized as a central mediator of programmed cell 
death, including necroptosis, in cardiovascular diseases27. CamKII can be a substrate of RIP 3, the main switch in 
necroptosis, during ischemia-reperfusion resulting in mPTP opening and cardiac cell death28. However, the role 
of necroptosis in cardiac response to BPA had not yet been explored.
In this study, we sought to evaluate if chronic administration of BPA had any effect on cardiac function. Since 
BPA induced cardiac damage might be secondary to vascular effects, here we explore whether BPA effects are 
direct, on cardiomyocytes, or indirect, on coronary vascular endothelium. In addition, the underlying molecular 
mechanism of these effects will be explored. Clarifying the relationships between BPA and coronary vascular 
function and the molecular mechanism involved in cardiac cell death may widen our understanding of BPA’s 
impact on cardiovascular disease.
Material and Methods
A detailed listing of the reagents and antibodies used through the study are provided in Supplementary Data.
Animals. Wild-type CD1 mice were purchased from Charles River (Wilmington, MA, USA) and housed in 
our animal facilities with four mice/cage located in isolated rooms. All animal procedures were approved by the 
University of Alcala Animal Care Committee and Autonomous Community of Madrid (experimental procedure 
007/16) and conformed to the EU Directive regarding the protection of animals used for experimental and other 
scientific purposes (enacted under Spanish law 1201/2005). CD1 male mice of 8 weeks (~30 g weight) were used.
Ethanol dissolved-BPA was added to the drinking water at final concentration of 4 × 10−5 M. CT consisted of 
an equivalent volume of ethanol (final concentration 0.01%) in drinking water. This value delivers BPA ≤ 50 mg/
kg animal weight/day considered a low dose29. Only male mice were included in our study.
To study the BPA effects on cardiac necroptosis, we randomly divided mice into 2 groups: necrostatin- 1 
(NEC) or vehicle control group (CT). Some were administered BPA as above for 4 to 8 weeks (BPA + NEC 
and NEC). Necrostatin-1 was injected intraperitoneally 3 mg/kg animal weight/day, 3 days a week, as reported 
elsewhere30.
cell cultures. Murine aortic ECs (MAECs) were isolated from mouse aorta, as previously reported31. Briefly, 
the aortas were sectioned into 2-mm pieces, deposited in Matrigel solution, and fed with fresh growth medium 
for seven days [DMEM/HAM´s medium, 20% FBS, 0.05 mg/mL penicillin/streptomycin, and 2.5 μg/mL ampho-
tericin]. The tissue was removed, and 500 μL of Cell recovery solution was added to each culture. The Matrigel 
layer was removed and poured on ice for one hour. The solution was centrifuged at 4 °C, resuspended in 4 mL 
of growing medium, and plated. MAECs were selected by their ability to express the intercellular adhesion 
molecule-2 (ICAM-2) protein and purified with a flow cytometry cell sorter (DAKO)32. Purification was verified 
by confocal microscopy of MAECs double-stained with Von Willebrand factor antibodies.
H9c2 cells, a myoblastic cell line derived from embryonic rat myocardium, were cultured in the L-glutamine 
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 0.05 mg/mL penicillin/streptomycin 
in a humidified CO2 incubator with 5% CO2 at 37 °C33.
Cardiac myocytes and non-myocytes Isolation from the mouse heart. In order to elucidate the 
effect of BPA in mouse coronary endothelial cells, cardiac myocytes and non-myocytes cellular fractions were 
isolated from the mouse heart following the method described by Ackers-Johnson M, et al.34. Briefly, hearts from 
CT and BPA mice were perfused with a high EDTA buffer, excised from the circulatory system, and transferred 
to a 60 mm plate containing EDTA buffer. Digestion was achieved by injection of collagenase solution into the left 
ventricle (LV). When digestion was observed, the atria and right ventricle were carefully removed, and the left 
ventricle mechanically dissociated. Enzimatic activity was blocked with stop buffer and the cell suspension was 
passed through a 100-μm filter, followed by four sequential rounds of gravity settling.
The cell pellet in each round was enriched with myocytes and ultimately formed a highly pure myocyte frac-
tion, whereas the supernatant from each round was combined to produce a fraction containing non-myocyte 
cardiac populations. Non-myocytes cells were characterized by immunofluorescence staining of the endothe-
lial marker CD31 and α-smooth muscle actin. CD31 positive cells quantification was performed, counting six 
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different homogeneous fields that contain a mean of 60 cells/field. Endothelial cells represents the 73 ± 1.23% of 
the nonmyocytes fraction. Myocytes and non-myocytes fraction were lysed using protein lysis buffer and ana-
lyzed by western blotting.
ecG recordings. Mice were anesthetized with isoflurane (2% in pure O2). Fine needle electrodes (25 G) were 
inserted subcutaneously at the level of both armpits and left groin and connected to an AC amplifier (Cyberamp, 
Axon Instruments). The ECG leads were placed initially in the lead II configuration and exchanged when 
required, to the lead I and lead II at the pre-amplifier. The signals were amplified 500 times and band-pass filtered 
between 1 Hz and 100 Hz, digitized at 1000 Hz (Power 1401, CED, UK) and stored for off-line analysis using Spike 
2 software (CED, UK)35.
echocardiography. Mouse hearts were visualized by echocardiography by using a Vivid Q ultrasound sys-
tem (GE healthcare) equipped with a 12.5 MHz scan head. Mice were anesthetized with 1.5% isoflurane gas, 
resulting in a heart rate of approximately 400 beats/min. Parasternal short-axis-view images of the heart were 
recorded in a B-mode to allow M-mode recordings by positioning the cursor in the parasternal short-axis view 
perpendicular to the interventricular septum and posterior wall of the left ventricle36. From these recordings, 
the following parameters were determined using the on-site software cardiac package: systolic and diastolic 
Interventricular septum thickness (IVS), systolic and diastolic left-ventricle internal diameter (LVID), systolic 
and diastolic left-ventricle posterior Wall thickness (LVPW), left-ventricle ejection fraction (EF), left ventricle 
shortening fraction (FS), heart rate (HR), and cardiac output (CO).
Dobutamine stress test. Mice were injected a maximally effective dose of the β -AR agonist, dobutamine 
(3 μg/g)37. Inotropic and chronotropic responses to this stimulation were verified in all mice by echocardiography 
and ECG recordings of DI and II for 15 min.
Blood pressure. Indirect measurements of blood pressure were obtained in conscious animals using a 
tail-cuff sphygmomanometer (LE 5001 Pressure Meter; Letica Scientific Instruments, Hospitalet, Spain)23. The 
animals were trained for 5 d before starting the measurement to prevent stress and were pre-warmed to 30 °C 
with a heater (LE5660/6, Letica Scientific Instruments, Hospitalet, Spain). Arterial pressure was measured 
several times between 9:00 and 12:00 AM, and pressure values were considered acceptable at ten consecutive 
measurements.
Vascular permeability assay. Evans blue is vital dye used to study blood vessel and cellular membrane 
permeability38. Evans blue was injected IP, 24 hours before euthanization, to allow circulation. The striking blue 
color can be identified the EBD-albumin conjugate within the tissue ex-vivo39. To extract Evans blue dye, 250 µL 
deionized formamide was added to the dry tissue and incubated overnight in an oven or a heating block at 55 °C, 
then loaded into a 96-well plate for absorbance reading with a spectrophotometer. Evans blue was also detected 
by confocal microscopy of the LV sections due to the fluorescence spectrum of this product (620 nm excita-
tion/680 nm emission)40.
Histology. LV sections were fixed in a 10% formalin solution, dehydrated in ethanol, and then embedded 
in paraffin as previously described36. Tissue sections (5 μm) were obtained in a microtome, were deparaffinized, 
rehydrated, and stained with Masson’s trichrome staining kit (EMD Millipore Corporation, Billerica, MA, USA) 
and Sirius red staining (Sigma- Aldrich, San Luis, MI, USA) for fibrosis quantification. Hematoxylin/Eosin stain-
ing was performed to explore heart morphology (Sigma-Aldrich, San Luis, MI, USA).
Immunoblot. Protein lysates were immunoblotted as previously described41. Twenty-five μg of total protein 
was separated in a 10% SDS-polyacrylamide gel electrophoresis. For protein detection, blocked membranes were 
incubated with specific antibodies, washed, and incubated with a secondary antibody. The bands were visualized 
with the Super-Signal detection kit (Pierce, Waltham, MA, USA).
Immunohistochemistry. Samples were boiled in retrieval buffer for 20 min after xylene deparaffinization. 
Master polymer plus detection system (Master Diagnostica, Madrid, Spain) was used, and antibody incubation 
was overnight at 4 °C. Sections were incubated with secondary antibodies for 1 hour at room temperature and 
counterstained with Harry´s hematoxylin, dehydrated and mounted with DPX (Casa Alvarez, Madrid, Spain)42. 
Images obtained of at least five different hearts per condition (6 per animal) were taken for data quantification 
using bright-field microscope (Eclipse 50i; Nikon, Tokyo, Japan).
Confocal microscopy. Slides containing tissue sections were incubated with the primary antibodies over-
night 4 °C. After washing with PBS, the slides were incubated with FITC, Alexa-488, or Alexa-647-conjugated 
secondary antibodies for 1 hour at room temperature. Nuclei were stained with Hoechst. Images were taken for 
data quantification using a Leica TCS SP5 confocal microscope (UAH-NANBIOSIS-CIBER-BNN). At least five 
different fields per condition were obtained.
Analysis of capillaries densities in the myocardium. For blood vessel counting heart sections obtained 
from CT and BPAtreated mice were stained with CD31 antibody as described previously43. Sections (6 μm) were 
blocked with 5% BSA for 30 min and, incubated with CD31antibody, a specific marker of endothelial cells over-
night at 4 °C and the secondary antibody Alexa fluor 647 was added for 1 hour, room temperature light protected. 
The samples were incubated with FITC–conjugated wheat germ agglutinin (WGA) (Life Technologies, Carlsbad, 
Ca, USA) to delimit cardiomyocyte plasma membrane for 1 hour and Hoechst was added to localized the nuclei. 
Images of subepicardial regions of the left ventricular (LV) wall and the interventricular septum (IVS) on the 
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section were obtained by confocal microscopy (Leica TCS SP5). Positive CD 31 endothelial cells were quantified 
from at least six random high-power fields from different heart regions (left ventricle, right ventricle, and septum) 
by a blinded investigator. The capillary count was analyzed with Fiji44. The results were presented as capillary 
density per field for each heart region analyzed.
Cell transfection. MAECs were transfected with 50 nM non-targeting siRNA(si-Scramble) or RIP 
3-targeting siRNA (si-RIP 3) (Santa Cruz Biotech, Santa Cruz, CA, USA)45 using Lipofectamine 2000 transfec-
tion reagent and Opti-MEM (Gibco, Waltham, Ma, USA) for 6 hour. Following 24 hours transfection, cells were 
incubated with BPA in 5% serum DMEM culture medium for 24 hours at 37 °C, 5% CO2.
Survival, apoptosis and necrosis assay. An MTT assay was used to measure cell viability46. Briefly, 
MAEC (6000 cells/well) were seeded in 24-well plates overnight and were then incubated with various con-
centrations of BPA at 37 °C for 24 h. MTT (0,5 mg/mL) was added to each well. After three hours incubation, 
supernatants were removed, and 150 µL DMSO was added to each well as a solvent. Absorbance was measured 
at 492 nm in a spectrometer plate reader (ELx800, Bio-Tek Instruments, Winooski, VE, USA). Non treated cells 
(control group) were regarded as having 100% viability.
To determinate cell death in tissue, we use DeadEnd™ Fluorometric TUNEL System (Promega, Madison, WI, 
USA) following the manufacturer instructions, in combination to Polyclonal Rabbit Anti-FITC/HRP, the stain 
was developed by addition of DAB substrate (Dako, Santa Clara, CA, USA). Samples were counterstained with 
Mayer’s hematoxylin and mounted with DPX and visualized in a bright field microscope (Eclipse 50i; Nikon, 
Tokyo, Japan). Images (2 sections, n = 5 animals/group). Five slide fields were randomly examined using a defined 
rectangular area under 40 × magnifications. Apoptotic cells were counted under 400 × magnifications. Results are 
expressed as the percentage of TUNEL-positive cells versus the total number of cell nuclei per field47.
Necrosis and apoptosis determination by flow cytometry were performed in cells treated with BPA and 
silenced for RIP3 or a siRNA scramble as control. The cells were trypsinized and resuspended in 150 μl of 
1 × binding buffer. Then 5 μl of 20 μg/mL Annexin V-FITC conjugated and 5 μl of propidium iodide (PI) were 
added and cells incubated for 15 minutes in the dark at room temperature according to manufacturer´s instruc-
tions. Cells were analyzed by FACS Calibur (Becton, Dickinson Company, NJ, USA). The percentages of cells in 
each quadrant were analyzed using Cyflogic software (Cyflo Ltd, Turku, Finland). Results of flow cytometry were 
obtained by calculating the number of necrotic cells (PI+/Annexin−) and apoptotic cells (PI−/Annexin+). Double 
negative were considered live cells and annexin V+-PI+ were late apoptotic or necroptotic cells. All the results 
experiments were performed in duplicate and repeated at least three times.
mRNA expression. Total RNA from cardiac tissue was extracted with TRIzol reagent from Invitrogen 
Corporation (Carlsbad, CA, USA) following the manufacturer´s instructions. First-strand cDNA was synthesized 
from 2 μg of total RNA in a 20 μl reaction mixture using the High Capacity cDNA reverse transcription kit, and 
the qPCR reaction was performed with SYBR select master mix both of Life technologies (Carlsbad, CA, USA). 
The qPCR conditions and primers that were used are included in the Supplementary Information Table 1.
Statistical analysis. Every experimental condition was duplicated within each experiment, and each exper-
iment was repeated at least three times. For animal studies, n values refer to the number of individual animals 
used. Comparisons were made by analysis of variance, followed by Dunnett’s modification of the t-test when 
comparisons were made with common control and the unpaired two-tailed Student’s t-test for other comparisons. 
Results are expressed as mean ± SD, and differences were considered statistically significant at p < 0.05.
Results
BPA impaired cardiac function and induced cardiac hyperhrophy. Previously, we had reported that 
oral administration of BPA at different concentrations induced hypertension in mice as early as five weeks start-
ing at 4 × 10−7 M BPA and reaching a maximum effect at 4 × 10−5 M BPA23. We tested whether more prolonged 
exposure to BPA may negatively affect cardiac function. Mice were orally exposed to 4 × 10−5 M of BPA in the 
drinking water for 4, 8, and 16 weeks and cardiovascular functional abnormalities were examined. To assess the 
effect of BPA on cardiac conduction, we performed surface ECGs on CT (n = 10), and BPA treated mice (n = 18) 
(Fig. 1A). Interestingly, BPA treated mice displayed increased heart rate (526.25 ± 49.08 vs. CT = 440 ± 28.28; 
p < 0.001), and a significantly prolonged PQ interval and PR segment suggesting a first degree AV block.
Echocardiography analysis revealed that cardiac contractility was significantly impaired in BPA treated 
mice, as demonstrated by decreased ejection fraction (EF) (Fig. 1B) and fractional shortening (FS) (Fig. 1C). 
Besides, diastolic and systolic Interventricular septum thickness (IVSd) were increased, suggestive of cardiac 
hypertrophy (Fig. 1D). Left ventricular posterior wall thickness was slightly, but not significantly, elevated. 
However, end-diastolic but especially end-systolic internal diameter was augmented in animals treated for 8 and 
16 weeks with BPA (Supplementary Fig. S1A,B). These results indicates that besides a contractile dysfunction, 
BPA also induced a slight increase in ventricular size, consistent with ventricular hypertrophy. As expected, BPA 
also increased systolic and diastolic blood pressure (BP) after 4 weeks, and, was further elevated at 16 weeks 
(Supplementary Fig S1C).
Consistent with the functional findings, the hearts were significantly enlarged after 16 weeks of BPA treatment, 
as detected by heart weight-to-tibial length ratio and hematoxylin and eosin sections (Fig. 1E). Cardiomyocyte 
cross-sectional area measured by Wheat Germ Agglutinin (WGA) staining was also increased, especially at the 
interventricular septum and left ventricle wall, indicating cardiac hypertrophy (Fig. 1F). Cardiac fibrotic remode-
ling was not found in BPA hearts when compared with CT mice (Fig. 1G upper pannel) and Col I expression was 
modestly increased in cardiac tissue at 8 and 16 weeks of BPA administration (Fig. 1H). However, perivascular 
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Figure 1. BPA induced impaired cardiac function and cardiac hypertrophy. ECG and echocardiography were 
performed in CT (vehicle treated) and BPA treated mice for 4, 8, and 16 weeks. (A) Left panel: Representative 
ECG recording in DII showing a longer PQ interval in 4 weeks BPA treated mice compared to CTmice. Right 
panel shows mean values for PQ interval and PR segment from ECGs recorded after 4 weeks of treatment 
(CT n = 10 and BPA n = 18, *p < 0.05). (B–D) shows LV ejection fraction (EF), Fractional shortening (FS) 
and interventricular septum thickness respectively (CT n = 12 and BPA n = 6–10) *p < 0.05 vs. CT; (E) Upper 
panel: Representative images of hematoxylin and eosin in heart sections from mouse after 16 weeks of BPA or 
CT showing IVS enlargement. Scale bar: 1000 μm. Lower panel: Quantification of heart weight to tibial length 
ratio (mg/mm) of CT and BPA treated mice at the indicated time points. (CT n = 12 and BPA n = 6–10 mice 
per group). *p < 0.05 vs. CT; # p < 0.05 vs. BPA 4 weeks (F) Upper panel: Representative images of wheat germ 
agglutinin (WGA)-fluorescein isothiocyanate-staining in mouse hearts after 16 weeks of treatment showing 
cardiac myocyte (CM) cross-sectional area at different heart regions (LV wall and interventricular septum, 
IVS). Scale bars: 20 μm. Lower panel: Quantitative data of CM hypertrophy cell surface area (n = 8–12 hearts 
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fibrosis was significantly increased after eight weeks of BPA (Fig. 1G lower panel). Together these results indicate 
that BPA increased heart rate, impaired cardiac contractility, and induced cardiac hypertrophy.
BPA induces cardiac ischemia under stress and chronic cardiac inflammation. To test the patho-
physiological implication of our findings, we performed a dobutamine stress echocardiography study in our BPA 
treated mice. Following administration of dobutamine (DB), heart rate (HR) increased significantly from base-
line values in CT mice, but not in BPA treated mice, suggesting a BPA-mediated impairment of chronotropic 
responsiveness to β-adrenergic stimulation (Supplementary Fig. S2A). This effects was confirmed by the analysis 
of surface electrocardiogram in which shorter R-R intervals in response to DB challenge were observed only 
in CT mice, while R-R intervals failed to decrease further in BPA-treated mice when compared to BPA resting 
values (Fig. 2A). Moreover, the depressed ST segment, indicative of cardiac ischemia, was evident in most ani-
mals treated with BPA, suggesting that the coronary reserve may also be compromised (Supplementary Fig. 2B). 
Additionally, a DB challenge markedly reduced cardiac contractility after 16 weeks of BPA, as evidenced by the 
inability to increase the EF (Fig. 2B), the cardiac output (Supplementary Fig. S2C), and the left ventricular diam-
eter, compared with CT mice (Fig. 2C). Altogether, BPA reported abnormal stress test results, which might be 
indicative of cardiac ischemia.
Cardiac inflammation plays a critical role in adverse cardiac remodeling, as observed in ischemic heart dis-
ease, cardiac hypertrophy, and heart failure48. Hematoxylin and eosin sections of cardiac tissue from BPA-treated 
mice revealed an inflammatory response as early as four weeks of treatment, in which localized foci of CD68+ 
and Mac-2+ macrophage infiltrates were detected. Increased oxidative stress as detected by 4-Hydroxynonenal 
(4-HNE) was also present after 16 weeks, which might contribute to BPA-induced myocardial injury (Fig. 2D).
Since mice after 16 weeks of BPA still presented significant inflammatory infiltrates, we explored whether 
BPA may prevent macrophage polarization toward a phenotype of inflammatory resolution. A qRT-PCR analysis 
showed that M1 markers (Tumor necrosis factor-alpha (TNF-α) and CCL2 (Fig. 2E,F) and Chemokine (C-C 
motif) ligand 7 (CCL-7), Chemokine (C-C motif) ligand 12 (CCL-12) (Supplementary Fig. S3A,B), significantly 
increased in BPA treated mice hearts. CCL2 receptor (CCR2), transcript levels were significantly increased at 
four weeks of BPA, even before the onset of clinical manifestation of heart disease, and remained elevated after 
16 weeks of BPA (Fig. 2G). Confocal analysis showed the colocalization of CCR2 with CD68 macrophages in the 
hearts of mice at eight weeks of administration of BPA (Supplementary Fig. 3C,D). The accumulation of CCR2+ 
macrophages may represent a delay in polarization to M2 resolving macrophages49, and our data indeed indicate 
that M2 markers, including TFG-β and IL-10, were not increased even after 16 weeks of BPA (Fig. 2H,I).
BPA induces myocardial hemorrhage and vascular leakage. Hematoxylin and eosin staining of heart 
sections from the BPA mice, exhibited a distinctive phenotype (Fig. 3A). Most of the hearts showed early signs 
of cardiac interstitial edema with significant disarranged myocardial fibers along with the presence of inflam-
matory cells (Fig. 3Ab). Interestingly, hemorrhage was apparent in 75 ± 2% of the hearts, as evidenced by the 
interstitial presence of red blood cells (Fig. 3Ac) with fibrin deposits (Fig. 3Ad), indicative of microvascular 
damage. Hemorrhagic lesions could be observed as early as four weeks after BPA administration. Large areas 
of hemorrhagic foci together with fibrin deposits were evidenced after 8 weeks of BPA treatment that were still 
present in the hearts of mice after 16 weeks, although the hemorrhagic lesions were not as extensive compared 
to 8 weeks (Fig. 3Ae,f). A similar effect could also be observed in BPA treated mice at lower doses (4 × 10−8 and 
4 × 10−7 M), which mimic environmental exposure (Supplementary Fig. 3A). A positive fibrinogen staining near 
coronary arteries was observed, indicating plasma extravasation (Fig. 3B). In addition, cardiac vascularization 
in BPA hearts was significantly reduced as detected by decreased number of CD31 positive cells (Fig. 3C). In 
order to exclude BPA-induced coagulation defects, total platelet counts and coagulation tests (Prothrombin time 
(PT), Activated partial thromboplastin time (aPTT), Thrombin time(TT) and fibrinogen quantitation) were per-
formed, but the results were similar for both groups CT and BPA. Hence, coagulation abnormalities could be 
excluded as the origin of cardiac hemorrhages (Supplementary Fig. 3B–E).
To investigate whether BPA could promote structural changes in endothelial cells, we visualized CD31 positive 
endothelial cells within hemorrhagic areas by confocal microscopy. We observed gaps in the endothelial layer of 
injured vessels (Fig. 3D), which suggest that BPA could modulate the endothelial barrier function. Next, we ana-
lyzed the permeability of endothelial cells by Evans blue (EB) dye extravasation, observing that EB extravasation 
increased by a 1,5-fold in hearst from 4 and 8 weeks-BPA treated mice compared to CT. Iinterestingly, in the lungs 
EB extravasation was increased by 3-fold compared to CT (Fig. 3E). EB levels in livers and kidneys were similarly 
elevated in both BPA and CT mice due to fenestrated endothelium (not shown). EB extravasation in cardiac tis-
sue was also observed by confocal microscopy (red fluorescence of EB), and coronary arteries were stained with 
α-smooth muscle actin antibody (α-SMA, green). Whilst EB staining was confined to he lumen of the coronary 
arteries in CT mice Fig. 3F(a,b), in BPA treated mice EB was detected in the outer wall of the coronary artery and 
intercalated between arterial muscle cells (Fig. 3Fc,d).
Together, these results demonstrate that BPA increased vascular permeability and induced vascular leakage 
that could account for hemorrhagic damage that, together with a reduced vascularization, might lead to cardiac 
hypoperfusion and myocardial ischemia.
per group with 300–600 CMs analyzed per heart). CM size was expressed as μm2. (G) Representative Masson 
Trichrome and Sirius red-stained sections of CT and BPA mice at 8 and 16 weeks showing perivascular fibrosis 
but not interstitial fibrosis in BPA treated mice. Scale bar = 60 µm. (H) Collagen type I protein expression 
measured by western blotting in whole heart tissue from CT and BPA treated mice. GADPH is used as loading 
control. The bar graph shows the average of n = 10 hearts per condition.
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Figure 2. BPA induces cardiac ischemia and chronic inflammation. CT and 16 weeks BPA treated were challenged 
with an i.p. injection of 3μg/g of dobutamine while recording cardiac activity by EGC for 15 min. (A) Graphic 
representation of the RR interval of CT and BPA mice before and after dobutamine administration (n = 4–6 mice 
per group). (B,C) Echocardiogram analysis of CT and BPA mice before and after dobutamine administration 
showing Left ventricular ejection fraction (EF) and Left ventricular internal diameter (LVI Diameter) respectively. 
The data are presented as mean ± SD (n = 4 per group, EF: *p < 0.05 vs CT pre Dobu and **p < 0.05 vs BPA 
predobu; LVID *p < 0.05 vs LVIDd). (D) Upper panel: Representative confocal images showing infiltration of 
CD68+ macrophages (red) and nuclear staining with Hoetch (blue) as detected by confocal microscopy in heart 
sections from CT and 4 weeks treated BPA mice. Middle and lower panels: Immunohistochemistry in heart 
sections from CT and 8 weeks treated BPA mice detecting Mac-2 (macrophage marker), and 4-HNE (oxidative 
stress marker) at 16 weeks BPA (n = 8 for both groups, Scale bar = 60 µm). (E–G) RT-qPCR of CT and 4, 8, and 
16 weeks BPA treated mice showing cardiac mRNA expression of: (E) CCL2 (MCP-1), (F) TNF-α and (G) CCR2 
(CCL2 receptor) (n = 8 per condition with triplicates in each determination, *p < 0.05 vs. CT). (H) Images 
representative of immunostaining of IL10 and TFG-β1 in hearts from CT and 16 weeks treated BPA treated mice. 
Similar results were obtained in triplicate heart sections from n = 4 animals per condition. (I) TFG-β1 protein 
expression measured by western blotting in whole heart tissue from CT and BPA treated mice. The bar graph 
shows the average of n = 6 hearts per condition.
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Figure 3. BPA induces hemorrhagic cardiac lesions, decreased vascularization, and vascular leakage. (A) 
Photomicrographs from hearts stained with hematoxylin/eosin of CT (a), BPA 4 weeks (b and c), BPA 8 weeks 
(d), and BPA 16 weeks (e and f). Asterisk mark extensive hemorrhagic areas with fibrin deposits. Arrows mark 
fibrin deposit between myocytes fibers (scale bar = 60 μm). (B) Immunohistochemistry of heart sections from 
CT and 8 weeks treated BPA mice stained for Fibrinogen. Scale bar = 25 μm (C) Blood vessel quantitation 
with an anti-CD31 endothelial cell marker in the heart of CT and 8 weeks BPA treated mice. CD31 + cells 
were labeled in red, and nuclei were labeled with Hoechst in blue. Three different heart regions were used to 
quantitate: RV, LV and IVS and at least 6 fields of each region were counted (n = 4 hearts per condition. Results 
are expressed as the number of CD31 + cells/mm2 and referred to CT). (D) Left panel: Representative confocal 
images from heart sections of CT and 8 weeks treated BPA mice showing immunostaining for CD31 (n = 4 
mice per condition). Right panel: Masson trichrome staining of the same regions. Arrows mark hemorrhagic 
foci close to the blood vessel in BPA treated mice. Images are representative of n = 4 hearts per condition. (E) 
Vascular permeability in the heart and lungs measured 24 h after injection of Evans blue 2% expressed as ng 
dye/mg of tissue and referred to CT. The data are presented as mean ± SD, n = 6 mice per group. *p < 0.05 vs 
CT. F) Representative confocal images from heart sections of CT and 8 weeks treated BPA mice after injection 
with Evans blue (red fluorescence) followed by immunostaining for α-SMA (green). Nuclei were labeled with 
Hoechst in blue (n = 4 mice per condition). (a and b) CT hearts sections obtained at different magnifications 
showed no signs of EB extravasation. (c) and (d) are different sections of coronary arteries of BPA hearts with 
extravasation areas. Scale bar = 25 μm (a and c) and 50μm (b and d). IL = intraluminal area and (*) marks areas 
of EB extravasation.
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Figure 4. BPA induces cardiac necroptosis. (A) Detection of cell death by tunel assay in heart slides of CT and 
8 weeks BPA treated mice. Brown staining indicates TUNEL-positive nuclei, and blue indicates living cells. A 
representative image of two regions of a heart sections is shown. Scale bar = 25 µm. Similar results were obtained 
in triplicate heart sections from n = 4 animals per condition. (B) Immunoblot detection of PARP-1, the 86 KDa 
cleaved form of PARP-1, procaspase, and 43 KDa active caspase 8 in total heart lysates from CT and BPA treated 
mice at 4, 8, and 16 weeks. GAPDH was used as a loading control. A representative immunoblot is shown. The 
densitometric analysis are shown below (data are shown as mean ± SD, n = 4 mice per condition). (C) Cardiac 
cross-sections were examined for activated caspase‐3 (red). WGA marked CM are green and Hoechst cell nuclei 
in blue. Representative images of findings in CT and 8 weeks treated BPA mice are shown (a total of 4 sections 
per heart were examined; n = 3 to 8 hearts per group. Scale bar = 50 μm). (D) RIP3 protein expression measured 
by western blotting in whole heart tissue from CT and BPA treated mice. GAPDH was used as a loading control. 
A representative immunoblot is shown. The densitometric analysis is shown below. Data shown represent each 
mouse cardiac RIP3 expression referred to CT (n = 8–12 mice per group, scale bar = 25 µm). (E) Representative 
confocal microscopy images of RIP3 (shown in red), in regions from CT and 8 weeks treated BPA mice. Scale 
bar = 25μm. The expression of Caveolin-3 was used as a cardiac myocyte cell marker (Cav3, in green). Nuclei 
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BPA induced vascular injury is mediated by RIP3/CamKII dependent endothelial cell necroptosis. 
Inflammation and cell death are associated with the development of heart disease, especially under increased 
oxidative stress conditions, as observed in BPA treated mice50,51. To identify the mechanisms underlying vascular 
leakage and myocardial hemorrhages induced by BPA, we performed tunel assay in hearts from 8 weeks BPA 
treated mice, observing increased cell death, especially at the coronary endothelium and within the vascular wall, 
compared to CT (Fig. 4A). There was a 2.8 ± 1.06 fold increase in total tunel positive cells in heart slides at 8 weeks 
after BPA treatment, while in areas containing coronary vessels, the increase is 9,89 ± 0.856 indicating a higher 
susceptibility of vascular cells to BPA induced cell death.
Western blot analysis of whole heart lysate showed neither changes in caspase 3 activity, as reflected by the Poly 
[ADP-ribose] polymerase 1 (PARP-1) cleavage, nor increased caspase 8 activity (Fig. 4B). Similarly, confocal micros-
copy analysis of CT and 8 weeks BPA heart sections revealed few differences in active caspase 3 levels (Fig. 4C), 
suggesting that an apoptosis-independent mechanism is involved in BPA-induced endothelial cell death.
To confirm that endothelial cells were not undergoing apoptotic cell death, we treated mouse aortic endothe-
lial cells (MAEC) with 0-10−4 M BPA for 24 h. BPA reduced cell viability from 10−7 M (Supplementary Fig. S5A). 
Therefore MAEC were treated with 10−6 M of BPA for 24, 48 and 72 h and the level of caspase 3 activity, as 
detected by PARP-1 cleavage, and as well caspase 8 were studied by western blot. We found no caspase activation 
in BPA treated cells compared to vehicle treated cells (CT) (Supplementary Fig. S5B). However, the treatment of 
cardiomyocyte cells (H9c2) with different concentrations of BPA during 24 h, did no reduce cell viability except at 
the highest concentration (10−4 M). (Supplementary Fig. S5C). Together, these results confirmed that BPA targets 
endothelial cells by an apoptotic independent form of cell death.
Interestingly, caspase-8 induces apoptosis but also serves as a significant regulator of necroptosis. Active 
caspase 8 can cleave RIP1 and 3, thus preventing necroptotic signaling52,53.To explore if necroptosis contributes 
to BPA induced coronary vessel injury, we investigated RIP3 levels in whole cardiac tissue of BPA treated mice. 
RIP 3 protein expression, which is critical to initiate necroptosis, was increased in the myocardium of BPA treated 
animals for 4,8 weeks and 16 weeks (Fig. 4D). Confocal microscopy revealed intense labeling of RIP 3 after 8 
weeks of treatment with BPA at the endothelial lining of coronary vessels and around blood vessels. However, 
RIP3 staining in cardiomyocytes was slightly more intense that in CT hearts (Fig. 4E).
To clarify which cardiac cells were contributing to increased RIP 3 expression, we isolated cardiomyocytes 
(CM) and non-myocyte cellular fractions from CT and 8 weeks-BPA treated mice. Non-cardiomyocyte cells 
consisted mostly in endothelial cells, as detected by positive CD31 staining and the absence of α-SMA staining. 
Although CM from CT and 8 weeks BPA treated mice showed no increase in RIP 3 levels, the endothelial cell 
fraction showed significant increased RIP 3 expression (Fig. 4F). Similarly, western blot analysis of RIP3 expres-
sion on H9c2 cells showed no differences between CT and BPA treated cells (Supplementary Fig. S5D). Together, 
those results indicate that BPA may initiate a RIP 3-necroptotic pathway in vascular cells.
Recently it has been described that necroptosis can proceed in a RIP 1 independent pathway, activating 
Ca2+-CamKII to regulate mitochondrial permeability transition pore (mPTP) opening54,55. The opening of the 
mPTP in response to ischemia-reperfusion injury has been linked to cell death in the heart and other organs56,57. 
Here we found that BPA increased CamKII phosphorylation in whole heart homogenates at 4 and 8 weeks of BPA 
treatment (Fig. 5A).
To better comprehend the relationship between BPA and cardiac necroptosis, we treated mice with BPA and the 
necroptosis inhibitor Necrostatin-1(NEC-1) for 4 and 8 weeks. Functional analysis revealed that necrostatin was 
able to partially revert the impairment in cardiac contractility caused by BPA (Fig. 5B). Histological analysis also 
evidenced a less pronounced cardiac injury compared with BPA treated mice with less oxidative stress as detected 
by 4-HNE staining (Fig. 5C, lower panels). More importantly, we found smaller hemorrhagic lesions (Fig. 5C H&E 
upper, and Masson Trichrome middle panels). NEC-1 treatment also produced a reduced inflammatory response 
compared to BPA alone, as detected by the expression of pro-inflammatory mRNA corresponding to TNF-α, CCR2 
and CCL2 (Fig. 5D). RIP 3 levels were studied in isolated EC protein samples, finding a reduction of RIP 3 expres-
sion in NEC-1 + BPA compared to BPA alone, which correlates with reduced p-CamKII expression in endothelial 
cells, indicating a link between BPA and induced endothelial RIP 3, CamKII activation, and cardiac injury (Fig. 5E).
BPA induced endothelial necroptosis is mediated by RIP3/CamKII pathway. We explored the 
implication of CamKII on endothelial cell necroptosis, using cultured mouse aortic endothelial cells (MAEC). 
BPA increased the expression of RIP 3 (Supplementary Fig. 5E), similarly to the response induced by BPA in the 
cardiac endothelial cell fraction. To test whether RIP 3 mediates BPA-induced necroptosis, RIP 3 expression was 
silenced by siRNA and cell death assayed by flow cytometry. Administration of BPA in RIP3-silenced MAEC had 
no effect on the number of apoptotic cells (annexin V+/PI−), but necroptosis (annexinV+/PI+) was signifi-
cantly reduced (Fig. 6A,B and Supplementary Fig. 5F), as well as the BPA-induced activation of CamKII (Fig. 6C). 
Pharmacological inhibition of CamKII activity with Kn-93 (KN) did not affect BPA induced RIP3 expression 
(Fig. 6D) but was able to decrease BPA induced necroptosis (Fig. 6E and Supplementary Fig. 6G). Thus, BPA 
stimulation of endothelial necroptosis proceeds via RIP 3 induction of CamKII signaling.
Taken together, these results suggest that BPA induces necroptosis in endothelial cells, contributing to coro-
nary damage, vascular leakage, and chronic inflammation leading ultimately to myocardial injury.
were stained with Hoechst (blue). Similar results were obtained in n = 4 hearts per condition. (F) RIP3 protein 
expression measured by western blotting in freshly isolated CM or EC from CT and 8 weeks BPA treated mice. 
The bar graph shows mean ± SD of RIP3/GADPH average refered to CT (n = 6 hearts per condition, *p < 0.05 
vs CT in ECs).
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Figure 5. Necroptosis inhibition with necrostatin-1 reduces the adverse cardiac effects of BPA. (A) Left panel: 
representative immunoblot showing phosphorylated-CamKII and total CamKII protein expression in whole 
heart extracts from CT and BPA treated mice at 4 and 8 weeks. Right panel: densitometric analysis shown as 
mean ± SD (n = 4; *p < 0.05 vs control CT). Mice were treated with BPA and BPA and necrostatin-1 (NEC) for 
4 and 8 weeks. (B) Echocardiography was performed at indicated time points for LV Ejection fraction (EF) and 
fractional shortening (FS) measurement (BPA n = 8 and BPA + NEC, n = 6 mice per group; *p < 0.05 vs. time 0, 
**p < 0.05 vs. BPA 8 weeks). (C) Representative photomicrographs from hearts stained with hematoxylin/eosin 
to visualize hemorrhagic lesions, Masson´s trichrome to detect fibrosis, and 4-hydroxinonenal as a marker of 
oxidative stress (n = 6 animals per group). Asterisk mark extensive hemorrhagic areas. Scale bar = 60 μm. (D) 
RT-qPCR of CT, NEC, BPA and BPA + NEC 8 weeks treated mice showing cardiac mRNA expression of TNF-
α, CCL2 and CCR2 (n = 4 per condition with triplicates in each determination, *p < 0.05 vs. CT; **p < 0.01 
vs. BPA). (E) Immunoblot analysis of RIP 3, phosphorylated-CamKII and total CamKII protein expression 
in protein extracts from freshly isolated ECs from CT, NEC, BPA, and BPA + NEC treated mice at 8 weeks. 
A representative immunoblot is shown and densitometric analysis shown as mean ± SD (n = 6; *p < 0.05 vs 
control CT; **p < 0.05 vs BPA).
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Discussion
In this study, we investigated the mechanism of BPA-induced damage in male mice hearts. Our results demon-
strate that chronic administration of BPA causes hypertension and cardiac hypertrophy, leading to impaired 
cardiac function and cardiac hemorrhage. We have uncovered a novel pathogenic role of BPA to induce coronary 
endothelial cell death by necroptosis through the RIP3-CamKII pathway causing vascular leakage leading to 
cardiac hypoperfusion.
Figure 6. BPA induces endothelial cell necroptosis via RIP3/CamKII. (A,B) Flow cytometry analysis of MAEC 
transfected with RIP3-specific siRNA (si RIP3) or non-silencing siRNA scramble (si sc) and treated with BPA at 
10−6 M and 10−5 M for 24 h. Cells were stained with annexin V-FITC and propidium iodide. Data are shown as 
mean ± SD (n = 4 per condition with duplicates in each determination). (A) apoptotic cells annexin V+/IP− (ns; 
non significant) and (B) annexin V+/PI+ cells. (*p < 0.05 vs. CT si sc, **p < 0.05 vs. BPA). (C) Immunoblot 
analysis of phosphorylated-CamKII, total CamKII, RIP3, and GADPH protein expression in CT and BPA 
(10−6 M) treated MAEC transfected as above. A representative experiment is shown (n = 4). Data are expressed 
as mean ± SD and referred to CT, *p < 0.05 versus CT siRNA-scramble MAEC; **p < 0.05 vs CT SiRNA RIP3. 
(D) Immunoblot analysis of RIP 3 and phosphorylated CamKII and total CamKII protein expression in protein 
extracts from MAEC treated with vehicle (CT), 10−6 M BPA (BPA), KN-93 (inhibitor of CamKII, 10−6 M) and 
BPA + KN for 24 h. A representative experiment is shown (n = 4). Data are presented as mean ± SD and refered 
to CT; *p < 0.05 vs. CT;**p < 0.05 vs. BPA. (E) Flow cytometry analysis of MAEC treated with vehicle (CT), 
BPA, KN-93, and BPA + KN for 24 h. Cells were stained with annexin V-FITC and propidium iodide. Data are 
shown as mean ± SD and referred to CT (n = 4 with duplicates in each determination,*p < 0.05 vs. CT or KN 
and **p < 0.05 vs. BPA AnexinV+PI+).
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In our mouse model, BPA induced heart dysfunction with reduced EF, FS, increased IVS thickness, abnor-
malities on cardiac electric conductivity, hypertension, and cardiac congestion. These results are in agreement 
with several reports describing a pro-arrhythmogenic effect of BPA in female rat hearts9,58 and impaired car-
diac function and contractility through alterations of myocyte calcium handling initiated by estrogen receptor15. 
Although only male mice were used in our study, an effect mediated by the estrogen receptor cannot be excluded 
entirely. Nonetheless, our results show that BPA slowed electrical conduction in male hearts with first degree AV 
block, which is in agreement with BPA effects reported by Posnack NG et al. in rat hearts59,60. In addition, life 
long administration of BPA in doses similar to human exposure also demonstrated an arrhythmogenic effect with 
evidence of cardiomyopathy61. This effect is relevant to human health since slowed conduction could represent a 
mechanism of reentrant arrhythmias, which can also cause tachycardia62 and could explain the increased heart 
rate observed in our mice.
Interestingly, the effect of BPA on electric conductivity has been found particularly pronounced under 
pathophysiological conditions such as stress or ischemic injury9,10. Indeed, dobutamine stress tests revealed that 
chronotropic and inotropic responses were impaired, and the coronary reserve seemed compromised in BPA 
treated mice. Since BPA may cause vasoconstriction due to a decrease in nitric oxide (NO) production and there-
fore decreased blood supply to the heart, ischemia could account for the arrhythmogenic behavior found in 
our study23. Besides, BPA treated mice might have a defect on the adrenergic signaling pathway, which could 
compromise Ca2+ homeostasis or in G-protein–coupled receptor signaling7. Moreover, BPA treated mice exhibit 
increased expression and activity of CamKII, which is also increased in animal models of heart failure and in 
humans in failing or arrhythmia-prone myocardium, pointing to a possible mechanism to explain BPA induced 
cardiac contractile dysfunction and arrhythmias55.
Our studies detected the infiltration of macrophages into the heart early after BPA treatment, accompanied by 
an increased expression of inflammatory cytokines CCL2, TNF-α, CCR2, CCL7 and CCL-12, markers of inflam-
matory M1 macrophages even at 16 weeks after exposure to BPA. CCR2+ macrophages could be detected at 8 
weeks. In animal models of pressure overload, CCR2+ macrophages play a critical role leading to subsequent car-
diac T-cell expansion, pathological LV remodeling, and late heart failure63. The presence of CCR2+ macrophages, 
together with reduced myocardial vascularization, may be indicative of defective reparative processes. In agree-
ment with our results, chronic administration of BPA or its substitute, Bisphenol S (BPS), can reduce active car-
diac remodeling in response to myocardial infarction, increasing metalloproteinase (MMP) expression in male 
mice12. Moreover, the exposure of resting monocytes to BPA increased polarization to activated macrophages64. It 
has also been reported that positive CCR2 macrophages enriched in the AV node may cause abnormal atrioven-
tricular electrical conduction65. Thus, recruitment of CCR2+ pro-inflammatory macrophages may also contribute 
to the arrhythmogenic AV block in response to chronic exposure to BPA.
Most studies about the cardiac effect of BPA focused on electrical conduction and structural or metabolic 
abnormalities on cardiomyocytes, however, data on its effects on cardiac endothelial cells are still missing. 
Interestingly, BPA cardiac effects presented accompanied by myocardial hemorrhage. Gear et al., described that 
female rats exposed to higher doses of BPA for six months developed a cardiomyopathy with hemosiderin con-
taining macrophages, indicative of previous microvasculature damage and hemorrhage11. However, the potential 
causes of BPA induced hemorrhages had not been investigated so far. Our first hypothesis was that BPA targeted 
the coagulation cascade, but none of the coagulation parameters were altered. Therefore,we speculated that hem-
orrhages could be secondary to ischemia and hypertension as cardiac hemorrhagic lesions have been described 
in response to ischemic reperfusion66. Here, we observed BPA-induced hemorrhagic foci already at 4 weeks, and 
although no ischemic events were detected in the ECG in resting conditions, after dobutamine challenge, 70% 
of the mice showed ST segments depression, indicative of cardiac ischemia. Furthermore, heart rate increased 
in BPA treated mice and some animals presented even further increases in HR after 8 weeks of BPA treatment. 
These conditions can contribute to increased oxidative stress, as detected by increased lipid peroxidation, and 
accumulation of oxidative insults could lead to endothelial wall injury mimicking the conditions present during 
ischemia-reperfusion. Accordingly, Aboul Ezz et al. reported increased lipid peroxidation, decreased glutathione 
(GSH) levels and catalase activity after 6 to 10-week BPA administration67. We also found decreased blood vessel 
density in BPA treated-mice, which, together with the increased cardiomyocyte mass, could also reduce myocar-
dial oxygen supply leading to ischemia.
The increased Evans Blue extravasation in the hearts and lungs of BPA treated mice support the hypothesis 
that BPA increases vascular permeability contributing to heart damage. Indeed, the extensive hemorrhagic areas 
observed at eight weeks also indicate vascular fragility and rupture of coronary microvessels. We have demonstrated 
that BPA decreases endothelial NO and increases oxidative stress leading to endothelial dysfunction and hyper-
tension23. Since BPA can cause hypertension in humans8 and mice23, another cause for the hemorrhages may be 
related to hypertensive degenerative or inflammatory changes affecting small arterioles, which could cause structural 
weakening and eventually vascular wall rupture. Studies on mouse models of hypertension-induced cerebral micro-
vascular hemorrhages (CMH) demonstrate that pathogenesis of the CMHs involves a weakening of the vessel wall 
by upregulation of MMPs or oxidative stress-dependent activation of MMPs, such as MMP2 and MMP968. Multiple 
lines of evidence suggest that NO regulates activation or expression of MMPs, and that decreased NO bioavailability 
promotes MMP activation in the vascular wall69,70. In the present study, we showed that hypertension increases at 
16 weeks. Although MMPs levels were not examined here, others have recently described in a model of lifelong 
exposure to BPA a decreased recovery after myocardial infarction associated with adverse cardiac remodeling due 
to increased MMP2 and MMP9 expression12. Besides, Belcher et al. reported that cardiac transcriptome after BPA 
exposure caused sex-specific dysregulation of the collagen extracellular matrix (ECM)7. Since BPA impairs NO 
production due to eNOS uncoupling, BPA could likely affect ECM turnover via NO signaling leading to a weak-
ening of coronary vascular wall, which in addition to ischemia, could be the culprit behind microhemorrhages. A 
detailed characterization of the molecular mechanism responsible for early microvascular hemorrhage is critical to 
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understand the cardiac effects of BPA, especially during cardiac ischemia, since myocardial hemorrhage has been 
associated with human adverse remodeling and adverse health outcome in the longer term71.
Here, we provide a potential mechanism for detrimental cardiac effects of BPA in vivo, finding the activation 
of necroptosis cascade as the cause of endothelial cell death leading to hypoperfusion and ischemia. Our data 
showed increased cell death in hearts from BPA treated mice, especially in the areas containing blood vessels, 
in the absence of increased apoptotic markers. Necroptosis is a newly discovered pathway of programmed cell 
death with an essential role in human ischemic injury72. RIP 3 is a critical determinant in the necroptotic pathway 
and is expressed in the myocardium73. The process of necroptosis is dependent on the activation of the RIP 1–
RIP 3–MLKL axis initiated by inflammatory TNF-α and other pro-apoptotic stimuli such as oxidative stress74. 
Our results establish a role for RIP 3 in BPA-induced endothelial cell injury since, since RIP 3 levels increased 
only in endothelial cells and perivascular areas while this protein was not found increased in cardiomyocytes. 
Nonetheless, we can not exclude a BPA role in RIP 3 mediated necroptosis in fibroblast or macrophages. The 
necroptotic pathway is also proven to relate to vascular disease as elevated RIP 3 levels are detected in ischemic 
stroke, atherosclerosis, and aortic aneurisms74. Interestingly, BPA decreased endothelial cell viability in a 
dose-dependent manner but failed to induce apoptotic cell death. In our study, gene silencing of RIP 3 reversed 
the effect of BPA on endothelial cell necroptosis. It has been reported that RIP 3 knockout decreases myocardial 
necroptosis in myocardial infarction73. Accordingly, the treatment of mice with BPA and the necroptosis inhibitor 
NEC-1 reversed cardiotoxic effects of BPA producing fewer hemorrhages and less inflammation. In support of 
our results, Chen J. et al. showed that NEC-1 prevented the disruption of the brain-blood barrier reducing brain 
hemorrhages75. However, NEC-1 only induced a moderate improvement of cardiac function so the possibility of 
a direct effect of BPA on myocardium by a different pathway cannot be completely ruled out.
Two mechanisms can contribute to BPA triggering the necroptotic pathway: early inflammation, which 
increased TNF-α, a known initiator of RIP 1/3 necroptosis, and, secondly, inhibition of caspase-8 activity which 
allowed RIP 3 phosphorylation and activation. Recent reports documented that RIP3 can also facilitate inflam-
mation independent of myocardial necrosis by releasing damage-associated molecular patterns (DAMPS)76. In 
our study, inflammation appears as early as 4 weeks and remains elevated after 16 weeks. Thus, RIP 3-induced 
necroptosis could be initiated by TNF-α and oxidative stress, and later could exacerbate the inflammatory con-
ditions induced by BPA in later stages. The necroptosis-inflammatory response might explain the lack of M2 
phenotype macrophages found at 16 weeks. This hypothesis is supported by the decreased inflammation found 
in BPA + NEC-1-treated mouse.
BPA-dependent cardiac damage could be initiated by inflammation and oxidative stress increasing CamKII 
activation. Moreover, oxidation of CamKII might be the primary mechanism for myocardial rupture following 
myocardial infarction77. Here we have shown increased activation of CamKII in hearts from 4 and 8 weeks BPA 
treated mice. CamKII activation by autophosphorylation and oxidation has been proposed as a potential mech-
anism to activate necroptosis and conversely CamKII has been proposed as an alternative substrate of RIP 3, 
Figure 7. Mechanism of the cardiotoxic effects of BPA. BPA induces early inflammation and oxidative stress 
leading to endothelial cell death. BPA activates the RIP 3-CamKII necroptotic pathway at endothelial cells. 
Necroptosis could be contributing to exacerbate the inflammatory conditions induced by BPA although direct 
effects on myocardium can not be excluded. Decreased endothelial barrier function and weakening of the 
coronary vascular wall in the setting of hypertension may cause ventricular hemorrhages, cardiac and lung 
congestion, ultimately leading to heart failure.
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leading to myocardial necroptosis during ischemia-reperfusion injury28. Our data demonstrate that inhibition 
of CamKII activity with KN-93 decreases necroptosis but does not affect BPA increased-RIP 3. However, RIP 
3 silencing prevented CamKII phosphorylation and necroptosis induction. Therefore our results point to RIP 3 
acting through CamKII to induce necroptosis in response to BPA.
In summary, our study provides a mechanism to explain the cardiotoxic effects of BPA. BPA activates the 
RIP 3-CamKII necroptotic pathway leading to endothelial cell death. Decreased endothelial barrier function 
and weakening of the coronary vascular wall in the setting of hypertension may cause ventricular hemorrhages, 
cardiac, and lung congestion, which ultimately led to heart failure (summarized in Fig. 7). Targeting the RIP 3 
pathway may have beneficial effects in BPA induced cardiac damage, mainly when associated with ischemia.
Our results are particularly interesting because exposure to this common environmental chemical could pose 
an additional risk for individuals with preexisting cardiac conduction abnormalities, cardiac disease, and other 
cardiovascular risk factors.
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